Economic evaluation of snake antivenom production in the public system

Journal of Venomous Animals and Toxins Including Tropical Diseases

Volumn 12, Issue 3, 2006, Pages 497-511

  Morais, V ^a   Massaldi, Hugo ^a,b  

^a Universidad de la Republica Instituto de Higiene   (Uruguay)

^b NONE   (Uruguay)

Author keywords

Antivenom; Economical cost; Equine plasma; Immunoglobulins; Serum production

Indexed keywords

ANIMALIA; EQUIDAE;

EID: 33749161875     PISSN: 16789199     EISSN: 16789199     Source Type: Journal    
DOI: 10.1590/S1678-91992006000300012     Document Type: Article

References (23)

1. BIOLOGICS. In: THE UNITED STATE PHARMACOPEIA. 24.ed. Rockville: USP, 1999. p. 2011.
2. CHENG A., WINKEL K., BAWASKAR HS., BAWASKAR PH. Call for global snake-bite control and procurement funding. Lancet, 2001, 357, 1132.
3. CHIPPAUX JP., GOYFFON M. Venoms, antivenoms and inmunotherapy. Toxicon, 1998, 36, 823-46.
4. CHIPPAUX JP., WILLIAMS V., WHITE J. Snake venom variability: methods of study, results and interpretation. Toxicon, 1998, 29, 1279-1303.
5. EINTERNZ EM., BATES ME. Snakebite in northern Cameroon: 134 victims of bites by the saw-scaled or carpet viper, Echis ocellatus. Trans. Rev. Soc. Trop. Med. Hyg., 2003, 97, 693-6.
6. EUROPEAN VIPER VENOM ANTISERUM. In: EUROPEAN PHARMACOPEIA. 1997. p. 1712-13.
7. HARMS AJ. The purification of antitoxic plasmas by enzyme treatment and heat denaturation. Biochem. J., 1948, 42, 390-7.
8. JADHAV SS., KAPRE SV. Antivenom production in India. Handbook of natural toxins, 5, Reptil and anphibian venoms. New York: Marcel Dekker, 1991: 584-608.
9. KRIFI MN., EL AYEB M., DELLAGI K. The improvement and standardization of antivenom production in developing countries; comparing antivenom quality, therapeutical efficiency, and cost. J. Venom. Anim. Toxins, 1999, 5, 128-41.
10. LAING GD., RENJIFO JM., RUIZ F., HARRISON RA., NASIDI A., GUTIERREZ JM., ROWLEY PD., WARRELL DA., THEAKSTON RGD. A new Pan African polyspecific antivenom developed in response to the antivenom crisis in Africa. Toxicon, 2003, 42, 35-41.
11. LAING GD., YARLEQUE A., MARCELO A., RODRIGUEZ E., WARRELL DA., THEAKSTON RDG. Preclinical testing of three South American antivenoms against the venoms of five medically-important Peruvian snake venoms. Toxicon, 2004, 44, 103-6.
12. MCNAMEE D. Tackling venomous snake bites worldwide. Lancet, 2001, 357, 680.
13. MONTEIRO R., DUTRA D., MACHADO O., CARLINI C., GUIMARÃES J., BON C., ZINGALI R. Bothrops jararaca snakes produce several bothrojaracin isoforms following an individual pattern. Comp. Biochem. Physiol., 1998, 120, 791-8.
14. 2 fragments. Toxicon, 1994, 32, 725-34.
15. MORAIS VM., MASSALDI HA. Effect of pepsin digestion on the activity of equine immunoglobulins. Toxicon, 2005, 46, 876-82.
16. PINHO FMO., PEREIRA ID. Ofidismo. Rev. Bras. Ass. Med., 2001, 47, 24-9.
17. RAW I., GUIDOLIN R., HIGASHI H., KELEN E. Antivenins in Brazil: Preparation. Handbook of natural toxins, 5, Reptil and anphibian venoms. New York: Marcel Dekker, 1991: 557-83.
18. ROJAS G., JIMENEZ JM., GUTIERREZ JM. Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production. Toxicon, 1994, 32, 351-63.
19. SJOSTROM L., AL-ABDULLA I., RAWAT S., SMITH D., LANDON J. A comparison of ovine and equine antivenoms. Toxicon, 1994, 32, 427-33.
20. THEAKSTON RDG., WARRELL DA., GRIFFITHS E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon, 2003, 41, 541-57.
21. VISSER LE., KYEI-FARIED S., BELCHER DW. Protocol and monitoring to improve snake bite outcomes in rural Ghana. Trans. R. Soc. Trop. Med. Hyg., 2004, 98, 278-83.
22. WILDE H., THIPKONG P., SITPRIJA V., CHAIYABUTR N. Heterologous antisera and antivenins are essential biologicals. Ann. Intern. Med., 1996, 125, 233-6.
23. WORLD HEALTH ORGANIZATION. Progress in the characterization and standardization of antivenoms. Geneve: WHO Offset Publ., 1981, 58, 1-44.